Wall Street sell-side research analysts covering Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares have recently provided various price target projections on where the stock might be going. According to them, the stock is expected to reach $40.538 on a consensus level within the next year, according to Zacks. The most bullish estimate sees the stock reaching $81 while the most conservative estimate stand at $22.
Zacks also gives an average broker rating based on the sell-side recommendations from the analysts who cover Valeant Pharmaceuticals International, Inc.. They give the company shares an ABR of 2.66. This is based on the 13 analysts taken into consideration by Zacks.
Earnings Estimates for Valeant Pharmaceuticals International, Inc. (NYSE:VRX)
Currently, Wall Street is projecting that the firm will post $1.79 earnings per share. This consensus number is also derived from Zacks. For the most recent period which ended on 2016-06-30, Valeant Pharmaceuticals International, Inc.'s EPS was reported as $1.4. This created a “surprise factor” -11.95% due to being $-0.19 apart from what Wall Street predicted. When actual numbers differ greatly from the consensus expectations, sharp movement in the stock price can often be seen in the hours or days following the report.
Investors will mark their calendars for 2016-10-17, the date when Valeant Pharmaceuticals International, Inc. (NYSE:VRX) are expected to release their quarterly results.
In the most recent session, The Coca-Cola Co (NYSE:KO) shares have traded -0.46%. Following the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent review, the stock has been noted $-1.13 away from the 50-day moving average of $42.67 and $-2.88 away from the 200-day moving average of $44.42. From a different angle, the stock has been recently recorded -11.86% off of the 52-week high of 47.13 and +1.94% removed from the 52-week low of 40.75.
Currently, Coca-Cola Company (The) Common has a price to earnings ratio of 23.90. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may show that the company is overvalued. A PEG Ratio near one may be viewed as fair value. The stock currently has a PEG Ratio of 10.23.
Price Target Update
Analysts polled by Thomson Reuters have set a consensus target price of $47.17 on shares. Target prices may vary from one analyst to another due to the various ways they may proceed to calculate future price targets. This is a near-term estimation for the next 12-18 months.